Centene vs HealthEquity
Add, change or remove companies; up to four.
KIRA’s take AI analyst
I put Centene and HealthEquity side by side, using each one’s latest annual report. Here is what stands out:
- Centene is the larger business, with $194.8B of revenue in fiscal 2025 against $1.3B for HealthEquity, about 148 times as much.
- Centene grew revenue faster (19.4%, against 9.5%).
- HealthEquity kept more of each dollar of sales as operating profit (24.6% operating margin, against −3.9%).
- HealthEquity turned more of its sales into free cash flow (34.7% FCF margin, against 2.2%).
- HealthEquity earned a higher return on the capital invested in it (8.9%, against −26.4%).
Who comes out ahead
Of the 9 measures where higher (or lower) is clearly better, how many each company leads.
Centene
CNC
2/9
Revenue growthShare count change
HealthEquity
HQY
7/9
5-year growthOperating marginNet marginFCF marginReturn on capitalReturn on equityPiotroski F-score
Side by side
Best in the row
| Latest fiscal year | CNC FY25 | HQY FY26 |
|---|---|---|
| Size | ||
| Market cap | $33.9B | $8.7B |
| Revenue | $194.8B | $1.3B |
| Free cash flow | $4.3B | $455M |
| Net income | −$6.7B | $215M |
| Growth | ||
| Revenue growth | 19.4% | 9.5% |
| 5-year growth | 11.9% | 12.4% |
| Share count change | −5.9% | −1.5% |
| Profitability | ||
| Gross margin | — | 69.5% |
| Operating margin | −3.9% | 24.6% |
| Net margin | −3.4% | 16.4% |
| FCF margin | 2.2% | 34.7% |
| Return on capital | −26.4% | 8.9% |
| Return on equity | −28.8% | 10.2% |
| Balance sheet | ||
| Net debt | −$2.8B | $639M |
| Net debt / EBITDA | — | 1.3x |
| Dividends and buybacks | $475M | $299M |
| Valuation & quality | ||
| P/E | — | 37.5x |
| Piotroski F-score | 5 | 9 |
Ten years
Revenue
Operating margin
Free cash flow
Return on capital
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.